Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
Company submitted a Form 144 reporting a proposed sale of 12,354 Restricted Stock Units on 04/02/2026. The filing lists prior Rule 10b5-1 sales by Daan Guido Maria Van Well of 684 shares on three dates in 2026 as examples.
Morgan Stanley Smith Barney LLC submitted a Rule 144 notice to sell 18,556 shares of common stock. The filing lists the shares as Restricted Stock Units with a reported aggregate figure of $93,522.24 and cites 68,486,338 shares outstanding as of 04/06/2026. The excerpt also lists multiple 10b5-1 sales by Zhenyu Xu between 01/13/2026 and 03/19/2026 (examples shown: 4,000 and 608 share trades with corresponding proceeds).
SOPH submitted a Form 144 notice disclosing a proposed sale of 6,335 shares of Common Stock tied to Restricted Stock Units through Morgan Stanley Smith Barney LLC, dated 04/06/2026. The filing also records prior 10b5-1 sales of 774 shares on 03/19/2026, with a reported value of $3,704.52.
Morgan Stanley Smith Barney LLC reported Form 144 trading activity tied to SOPH restricted stock units and 10b5-1 sales. The filing lists 14,556 shares of restricted stock units dated 04/02/2026 and 5,000 shares dated 08/18/2024, and multiple 10b5-1 sale transactions between 01/12/2026 and 03/19/2026.
The excerpt shows a series of 10b5-1 sales by Philippe Menu: transactions of 5,000 and 608 common shares on several dates with reported proceeds (for example, $22,592.50 on 03/12/2026 and $2,912.81 on 03/19/2026). The filing lists the broker and indicates the trades were executed under an automated plan.
SOPH affiliate filed a Form 144 notice to sell 8,797 shares of Common stock tied to Restricted Stock Units dated 04/02/2026, through Morgan Stanley Smith Barney LLC. The excerpt also lists three prior 10b5-1 sales by Manuela Valente of 380 shares each on 01/20/2026, 02/19/2026, and 03/19/2026 at $2,040.98, $1,833.88, and $1,818.34, respectively.
SOPH reported multiple secondary sales executed under a Rule 10b5-1 plan by a reporting person. The excerpt lists individual dispositions of Common stock between 01/07/2026 and 03/19/2026, including large blocks such as 95,488 shares for $491,626.46 on 01/09/2026. The filing also lists Restricted Stock Units of 78,583 and Founders Shares of 8,500 with grant dates shown.
SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma received new equity awards as part of his compensation. He was granted options to buy 119,760 ordinary shares at an exercise price of $5.04 per share, vesting 25% on April 2, 2027 and monthly through April 2, 2030. He also received 82,136 restricted stock units, with 25% vesting on April 2, 2027 and the remaining 75% in equal quarterly installments through April 2, 2030. These are awards from the company, not open-market purchases or sales.
SOPHiA GENETICS SA granted President Ross Muken equity-based compensation on April 2, 2026. He received options to buy 628,743 ordinary shares at $5.04 per share, exercisable until April 2, 2036, and 431,211 restricted stock units that convert into ordinary shares as they vest.
According to the vesting terms, 25% of the RSUs vest on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030. The share options vest 25% on April 2, 2027, then in equal monthly installments through April 2, 2030, contingent on continued service.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported new equity awards. He received a grant of 164,671 share options with an exercise price of $5.04 per share, and a separate grant of 112,936 ordinary shares in the form of restricted stock units.
The RSUs were granted under the company’s 2021 Equity Incentive Plan and vest over time, with 25% vesting on April 2, 2027 and the remaining 75% in equal quarterly installments through April 2, 2030, subject to continued service. The options vest as to 25% of the underlying ordinary shares on April 2, 2027, then in equal monthly installments through April 2, 2030, and expire on April 2, 2036. After these awards, Menu directly holds 112,936 ordinary shares and 164,671 share options from this filing.
Chief Scientific Officer Zhenyu Xu received new equity awards from SOPHiA GENETICS SA. On April 2, 2026, he was granted 112,936 ordinary shares as restricted stock units and a share option for 164,671 ordinary shares with a $5.04 exercise price.
The RSUs vest 25% on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030, subject to continued service. The option vests 25% on April 2, 2027, then in equal monthly installments through April 2, 2030, and expires on April 2, 2036. These are compensation-related grants rather than open-market purchases.